J Neurol Neurosurg Spine | Volume 5, Issue 1 | Short Communication | Open Access
Charles JA*
Holy Name Medical Center, Teaneck, NJ, USA
*Correspondance to: James A Charles
Fulltext PDFIntroduction: Painful peripheral neuropathy is usually an acquired condition with significant morbidity and inadequate treatment. In this study, we aimed to determine if blocking CGRP receptors present at the Dorsal Root Ganglion (DRG) with erenumab would benefit patients. Methods: We treated 15 subjects, mostly diabetic and idiopathic etiologies of painful neuropathy with erenumab 140 mg subcutaneously on a monthly schedule for 3 months. A washout period of 1 month of previous failed conventional therapies prior to our study was required. Using a 2 tailed paired t test, we analyzed the reduction in numeric pain score from baseline. Adverse effects were recorded. Results: The overall reduction in baseline neuropathic pain over 3 months in 13 subjects was 69.8%, (p<0.05). Two patients were non-responders. One patient had transient injection site pain. Conclusion: Compared to previous conventional therapies, erenumab was associated with a faster and more effective reduction in neuropathic pain with almost no adverse effects. These findings underscore the need for a large placebo-controlled study to determine if erenumab should be the preferred treatment of painful peripheral neuropathy.
Erenumab; Cgrp; Painful neuropathy
Charles JA. Treatment of Painful Peripheral Neuropathy with Erenumab - An Observational Study. J Neurol Neurosurg Spine. 2022; 5(1): 1023..